Lyra Therapeutics regains Nasdaq compliance as stock maintains $1 minimum

Published 23/06/2025, 13:48
Lyra Therapeutics regains Nasdaq compliance as stock maintains $1 minimum

Lyra Therapeutics, Inc. (NASDAQ:LYRA) has regained compliance with Nasdaq's minimum bid price requirement, according to an SEC filing released Monday. The stock currently trades at $10.45, showing strong momentum with positive returns over both one and three months, according to InvestingPro data.

The company received written notice from Nasdaq on June 13, 2025, confirming that its common stock maintained a minimum bid price of $1.00 or more for 12 consecutive business days, from May 28 to June 12, 2025.

As a result, Lyra has successfully addressed its previous non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Nasdaq has officially closed the matter.

Lyra Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. The company is registered as an emerging growth company under SEC regulations.

The information was disclosed in an 8-K filing submitted to the Securities and Exchange Commission.

In other recent news, Lyra Therapeutics announced successful results from its Phase 3 ENLIGHTEN-2 trial for LYR-210, aimed at treating chronic rhinosinusitis (CRS). The trial met its primary endpoint, demonstrating statistically significant improvements in CRS symptoms over a 24-week period. The positive results were observed as early as four weeks into the trial and were maintained throughout, with a safety profile comparable to the sham control. The ENLIGHTEN-2 trial's success contrasts with the earlier ENLIGHTEN-1 trial, which did not meet its primary endpoint. Analysts from H.C. Wainwright responded by raising their price target for Lyra Therapeutics to $16, maintaining a Neutral rating. Similarly, BTIG analysts also kept a Neutral rating, citing uncertainty regarding the approval pathway and the need for additional trials. Lyra Therapeutics plans to discuss a New Drug Application (NDA) submission with the FDA for patients without nasal polyps. The company is also considering a development plan for those with nasal polyps, with further regulatory feedback expected in the second half of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.